Related Experiment Video
Updated: Jan 15, 2026

09:19
NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
Published on: June 4, 2021
3.8K
Cell wall target fragment discovery using a low-cost, minimal fragment library
Kaizhou Yan1, Mathew Stanley1, Olawale Raimi2
1Division of Molecular, Cell and Developmental Biology, School of Life Sciences, University of Dundee, UK.
FEBS Letters
|January 14, 2026
Summary
We developed LoCoFrag100, a low-cost, accessible fragment library for crystallographic screening. This fragment-based drug discovery tool aids in identifying potential drug leads by assessing target ligandability efficiently.
Area of Science:
- Medicinal Chemistry
- Structural Biology
- Drug Discovery
Background:
- Fragment-based inhibitor design is a key strategy in drug discovery.
- Current fragment libraries face challenges with solubility, reactivity, cost, and accessibility.
- There is a need for cost-effective and readily available fragment sets for screening.
Purpose of the Study:
- To design and validate a low-cost, minimal fragment library (LoCoFrag100) for crystallographic screening.
- To assess the library's utility in identifying potential inhibitors for microbial enzymes.
- To provide an accessible tool for evaluating target ligandability in any laboratory setting.
Main Methods:
- Designed LoCoFrag100 with an average cLogP of 0.03 and cost of £20/g.
- Formatted the library in a 10x10 matrix to minimize Tanimoto similarity within 20 cocktails.
- Screened the library against three distinct enzymes involved in microbial cell wall synthesis using crystallography.
Main Results:
- Achieved hit rates of 1-6% across the three tested enzymes.
- Identified three fragments that show potential for further inhibitor development.
- Demonstrated the library's effectiveness in rapidly assessing target ligandability.
Conclusions:
- LoCoFrag100 is a practical and affordable fragment library for crystallographic screening.
- The library facilitates rapid assessment of target ligandability, aiding in early-stage drug discovery.
- LoCoFrag100 provides valuable data for prioritizing targets for subsequent inhibitor design and optimization.

